DIRA Treatment

NIAMS researchers Raphaela T. Goldbach-Mansky, M.D., M.H.S. (left) and Nicole Plass, R.N., M.P.A., U.S. Public Health Service, with a DIRA patient. NIAMS’ research has led to the identification and successful treatment of DIRA (deficiency of the interleukin-1 receptor antagonist), a genetic autoinflammatory disorder in children.

 

Credit: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health

Done